Diabetes mellitus (DM) is a metabolic disorder that occurs in the body because of decreased
insulin activity and/or insulin secretion. Pathological changes such as nephropathy …

Intercellular tight junctions represent a formidable barrier against paracellular drug
absorption at epithelia (eg, nasal, intestinal) and the endothelium (eg, blood–brain barrier) …

Simple Summary Exosomes derived from various sources can deliver therapeutic agents
such as small molecule drugs, nucleic acids, and proteins to cancer cells by passive or …

In view of the worldwide serious health threat of type 2 diabetes mellitus (T2DM), natural
sources of chemotherapies have been corroborated as the promising alternatives, with the …

Lipid based drug delivery systems (LBDDS) are valuable and biocompatible nano-carriers
for the vehiculation and potential delivery of various hydrophilic, hydrophobic, or amphiphilic …

The brain insulin metabolism alteration has been addressed as a pathophysiological factor
underlying Alzheimer's disease (AD). Insulin can be beneficial in AD, but its macro …

With the increasingly widespread of central nervous system (CNS) disorders and the lack of
sufficiently effective medication, meloxicam (MEL) has been reported as a possible …

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prevalent in
treating type 2 diabetes (T2D). However, owing to their limited oral bioavailability, most …

The biomedical use of nanoparticles (NPs) has been the focus of intense research for over a
decade. As most NPs are explored as carriers to alter the biodistribution, pharmacokinetics …

The lipophilic character of peptides can be tremendously improved by hydrophobic ion
pairing (HIP) with counterions to be efficiently incorporated into lipid-based nanocarriers …